FDA Approval for Mitral Heart Valve Technology Tendyne™ Achieves Final Milestone for Jean Boulle Medtech Following Abbott’s US$400 Million Acquisition
PRESS RELEASE Luxembourg, 30 May 2025 Jean Boulle Medtech (the “Company”), founder of Tendyne Holdings, Inc. (“TendyneTM”), is pleased to announce that its former investee company TendyneTM has received approval from the U.S. Food and Drug Administration (FDA) for the use of the transcatheter mitral valve replacement system to treat U.S. patients with mitral valve disease. Following…